Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma - Trial NCT03553537
Access comprehensive clinical trial information for NCT03553537 through Pure Global AI's free database. This Phase 3 trial is sponsored by Southwest Hospital, China and is currently status unknown. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Southwest Hospital, China
Timeline & Enrollment
Phase 3
Jun 01, 2018
Jul 01, 2021
Primary Outcome
Progression Free Survival
Summary
Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP
 (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma
 (PTCL).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03553537
Non-Device Trial